HealthcareServices

Ankylosing Spondylitis Global Forecast: Market to Scale Up to $9.42 Billion by 2030 at 8.3% CAGR

February 19, 2026February 19, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the ankylosing spondylitis market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Ankylosing Spondylitis Market in 2026, and what figure is it projected to hit by 2030?

The market for ankylosing spondylitis has demonstrated significant expansion in recent years. Its valuation is projected to increase from $6.34 billion in 2025 to $6.85 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.0%. Historically, this expansion has been driven by factors such as enhanced diagnostic recognition, broader accessibility of NSAIDs and DMARDs, the proliferation of specialist rheumatology offerings, wider access to hospital-based care, and the increasing application of imaging for monitoring the disease.

The ankylosing spondylitis market size is projected to experience substantial expansion over the upcoming years, with an anticipated growth to $9.42 billion by 2030 at a compound annual growth rate (CAGR) of 8.3%. This expansion during the projection period stems from factors such as the increasing acceptance of biologics and biosimilars, a heightened emphasis on personalized medical treatments, the growth of advanced biologic pipelines, a rising need for ongoing disease management, and greater investments in autoimmune research. Key trends anticipated during this forecast period encompass the increasing embrace of biologic therapies, the growing utilization of targeted DMARDs, a stronger emphasis on diagnosing the disease early, the broadening of personalized treatment methods, and improved incorporation of physical therapy initiatives.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11962&type=smp

Which Drivers Are Affecting Market Participation In The Ankylosing Spondylitis Market?

The ankylosing spondylitis market is set to expand due to an increasing incidence of autoimmune diseases. Autoimmune diseases represent a broad category of conditions where an abnormal immune response causes the immune system to mistakenly assault and harm healthy cells, tissues, and organs. These conditions, including ankylosing spondylitis, occur when the immune system erroneously targets the body’s own tissues, leading to inflammation and damage. Genetic predisposition and environmental factors both play a role in the emergence of ankylosing spondylitis, a form of autoimmune arthritis that primarily affects the spine and pelvis. For example, in September 2023, the Impact of IBD Report 2023, published by the IBD Clinical and Research Centre, a Canada-based organization focused on improving the lives of patients with Crohn’s disease and ulcerative colitis, reported that over 320,000 people in Canada had inflammatory bowel disease (IBD) in 2023, with a prevalence of 825 per 100,000. With the prevalence projected to increase by 2.44% annually, it is estimated that 1.1% of the population, or 470,000 Canadians, will be living with IBD by 2035. Therefore, the growing number of autoimmune disease cases will be a key driver for the future growth of the ankylosing spondylitis market.

What Segment Categories Are Covered In The Ankylosing Spondylitis Market?

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

What Industry Trends Are Transforming The Ankylosing Spondylitis Market?

Major companies engaged in the ankylosing spondylitis market are concentrating on developing advanced biologic solutions, such as biosimilars. This strategic focus aims to enhance patient access to treatment, reduce overall costs, and provide familiar administration options. Biosimilars are therapeutic agents that leverage the well-established active ingredients of reference biologics, thereby offering comparable efficacy and safety profiles. As an example, in August 2025, Amgen Biotechnology Singapore, a Singapore-based biotech firm, received regulatory approval for its biosimilar adalimumab (Amgevita), available in both a 40 mg/0.4 mL autoinjector and a 20 mg/0.2 mL prefilled syringe. This therapy is specifically indicated for alleviating signs and symptoms in adult patients with active ankylosing spondylitis who have not adequately responded to conventional therapeutic approaches. By providing familiar routes of administration, utilizing a recognized active ingredient, and presenting a more affordable alternative within the biologics landscape, these developments are set to impact the market.

Which Key Players Are Driving Competition In The Ankylosing Spondylitis Market?

Major companies operating in the ankylosing spondylitis market are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Which Region Is Projected To Lead The Ankylosing Spondylitis Market During The Forecast Period?

North America was the largest region in the ankylosing spondylitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Ankylosing Spondylitis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11962&type=smp

Browse Through More Reports Similar to the Global Ankylosing Spondylitis Market 2026, By The Business Research Company

Osteoarthritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Cervical Spondylosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

Axial Spondyloarthritis Axspa Market Report 2026

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795